stockrow
Saturday 7 November 2026
Export STLN’s income statement to Excel — free account
Starling Oncology, Inc.
STLN Healthcare Medical Care Facilities
Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024.
- Revenue
- +24.3%
- EPS
- +7.14%
- Free cash flow
- +167.1%
- Total debt
- −4.82%
Quarter to September 2026, against a year earlier
3.51
3.19
−47.61%
Follow STLN
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.07 | 0.95 | 0.57 | 0.65 | |
P/FCF ratio |
35.15 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
65.26 | 46.86 | (141.10) | 101.73 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.12 | 1.02 | 0.66 | 0.74 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
30.20 | 1,824.43 | (16.55) | (15.17) | |
EV/FCF |
37.06 | (182.11) | (14.03) | (13.42) | |
Quick Ratio |
0.79 | 1.14 | 1.13 | 1.31 | |
Current Ratio |
1.11 | 1.36 | 1.47 | 1.59 | |
Net Debt/EBITDA |
0.00 | (25.47) | (13.11) | (10.77) | |
Debt/Assets |
38.62% | 44.81% | 46.73% | 47.01% | |
Debt/Equity |
(1.94) | (3.21) | (4.83) | (4.92) | |
Asset Turnover |
3.53 | 3.47 | 3.29 | 2.98 | |
Operating CF/Net income |
(0.64) | (1.22) | 0.89 | (0.43) | |
Capex/Depreciation |
0.00 | (0.29) | (0.37) | (0.37) | |
Interest Coverage |
(1.64) | (2.48) | (3.37) | (3.60) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.93% | 18.57% | 19.13% | 19.75% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.10 | 0.11 | |
Share Based Compensation of Revenue |
0.79% | 0.66% | 1.14% | 0.93% | |
Graham Net Nets |
(0.13) | (0.13) | (0.22) | (0.21) | |
Graham Number |
1.53 | 1.28 | 1.15 | 1.46 | |
Earnings Yield |
(4.59%) | (5.52%) | (12.05%) | (15.73%) | |
Free Cash Flow Yield |
2.84% | (0.59%) | (8.23%) | (8.45%) | |
Revenue per Share |
1.62 | 1.57 | 1.45 | 1.54 | |
Operating CF per Share |
0.10 | 0.12 | (0.02) | 0.04 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.08 | 0.11 | (0.03) | 0.02 | |
Cash per Share |
0.35 | 0.40 | 0.30 | 0.36 | |
Shareholders Equity per Share |
(0.36) | (0.24) | (0.16) | (0.17) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.36) | (0.24) | (0.16) | (0.17) | |
Free Cash Flow |
8.88 | 11.03 | (3.26) | 2.17 | |
Working Capital |
13.99 | 34.05 | 37.51 | 41.79 | |
Capital Expenditures |
(1.26) | (0.91) | (1.04) | (1.06) | |
Net Current Asset Value |
(87.44) | (74.16) | (67.65) | (67.63) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
60.39 | 61.32 | 54.56 | 54.00 | |
Average Payables |
58.86 | 47.61 | 38.47 | 33.75 | |
Average Inventory |
27.76 | 17.90 | 18.30 | 13.46 | |
Average Assets |
175.70 | 169.02 | 166.12 | 168.69 | |
Average Common Equity |
(24.81) | (16.95) | (5.61) | (6.07) |
Columns are period end dates · fundamentals updated 6 Nov 2026